Concepedia

LingZhi Ma

LM

Statistics

Publications

17

Citations

1.3K

H-Index

14

Active since

2008

Affiliations

Moderna Therapeutics (United States)(Current)

National Institute of Allergy and Infectious Diseases

National Institutes of Health

Washington University in St. Louis

Simons Foundation

LingZhi Ma is an author at Moderna Therapeutics (United States) specializing in immunology, infectious diseases, and veterinary medicine.

ORCID

Publications per year

2008–2024

17

Publications

17

Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis

Angela Choi, Matthew Koch, Laurence Chu et al. · Nature Medicine · 2021 · 449 citations · Full text

, , +17

SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness

Kizzmekia S. Corbett, Darin K. Edwards, Sarah R. Leist et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2020 · 143 citations · Full text

, , +17

Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice

Baoling Ying, Suzanne M. Scheaffer, Bradley Whitener et al. · Cell · 2022 · 98 citations · Full text

, , +14

Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine Booster

Angela Choi, Matthew Koch, LingZhi Ma et al. · medRxiv · 2021 · 90 citations · Full text

, , +17

Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice

Angela Choi, Matthew Koch, Sayda M. Elbashir et al. · Vaccine · 2021 · 89 citations · Full text

, , +17

1–5 of 17